Summary
Phreesia, Inc. insider filings show Allison C. Hoffman, the company's general counsel and secretary, sold 14,483 shares of common stock on April 10, 2026, at $8.07 per share, producing $116,877 in gross proceeds. The filings also record a separate disposition on April 9, 2026, of 15,161 shares at $9.15 per share valued at $138,723; according to the Form 4 footnotes, those April 9 shares were withheld by Phreesia to meet tax obligations tied to the settlement of restricted stock units and did not constitute a sale by Hoffman.
Transaction details and holdings
The April 10 sale was carried out under a pre-established Rule 10b5-1 trading plan that Hoffman adopted on December 19, 2025. Following the April transactions and the withholding described in the filings, Hoffman is reported to directly own 163,485 shares of Phreesia common stock.
Share price context
These insider disclosures arrive while Phreesia shares are trading close to the company's 52-week low of $7.77 and have fallen more than 62% over the past six months. Market commentary cited in the filings references InvestingPro analysis indicating the stock may be undervalued at current levels, with the platform's Fair Value metric implying upside potential. The same analysis is noted to provide 16 additional recommendations for PHR, including commentary on the company's expected profitability growth this year.
Recent company results and outlook changes
Phreesia reported fiscal fourth-quarter 2026 revenue of $127.1 million, narrowly surpassing the consensus Street estimate of $126.6 million. Adjusted EBITDA for the quarter was $29.4 million, also ahead of the consensus figure of $28.1 million. Despite those beats, management reduced its fiscal 2027 revenue outlook by approximately 7%; the company attributes that revision to lower advertising spend commitments from pharmaceutical clients, which has a direct effect on its Network Solutions segment.
Analyst reactions
Following the earnings and guidance revision, brokerage reactions were mixed. Raymond James trimmed its price target to $16 while retaining an Outperform rating. BMO Capital lowered its target to $14 and also kept an Outperform rating. Citizens moved to downgrade the stock to Market Perform from Market Outperform. DA Davidson reduced its price target to $14 but maintained a Buy rating. In contrast, KeyBanc reiterated an Overweight rating with a $28 price target. These varied stances show a range of views among analysts in response to the company's recent disclosure and guidance change.
What the filings state
The Form 4 footnotes clarify that the April 9 disposition of 15,161 shares was a withholding by Phreesia to cover tax liabilities arising from the settlement of restricted stock units; that action did not represent a voluntary sale by Hoffman. The sale recorded on April 10 was executed through the previously adopted Rule 10b5-1 plan.
Context limitations
The filings provide the transaction records and the company's reported financials and guidance change. They do not elaborate on any further motives behind the trading plan or the timing of the reports beyond what is disclosed in the Form 4 and the company's earnings release.
Disclosure: